ChiCTR2300069142 版本V1.0 版本创建时间2023/03/08 02:50:08 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300069142 

最近更新日期:

Date of Last Refreshed on:

2023-03-08 02:50:02 

注册时间:

Date of Registration:

2023-03-08 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

鼻咽癌放疗后张口困难临床防控路径的构建

Public title:

Construction of clinical prevention and control path for radiation-induced trismus in nasopharyngeal carcinoma

注册题目简写:

English Acronym:

研究课题的正式科学名称:

鼻咽癌放疗后张口困难临床防控路径的构建

Scientific title:

Construction of clinical prevention and control path for radiation-induced trismus in nasopharyngeal carcinoma

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

曾谷清 

研究负责人:

王婷 

Applicant:

Guqing Zeng 

Study leader:

Ting Wang 

申请注册联系人电话:

Applicant telephone:

+86 15673427900

研究负责人电话:

Study leader's telephone:

+86 17873471540

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zengguqing0123@163.com

研究负责人电子邮件:

Study leader's E-mail:

1819990742@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖南省衡阳市蒸湘区常胜西路28号

研究负责人通讯地址:

湖南省衡阳市蒸湘区常胜西路28号

Applicant address:

28 West Changsheng Road, Hengyang, Hunan

Study leader's address:

28 West Changsheng Road, Hengyang, Hunan

申请注册联系人邮政编码:

Applicant postcode:

421001

研究负责人邮政编码:

Study leader's postcode:

421001

申请人所在单位:

湖南省衡阳市南华大学护理学院

Applicant's institution:

School of Nursing, University of South China, Hengyang, Hunan

研究负责人所在单位:

湖南省衡阳市南华大学护理学院

Affiliation of the Leader:

School of Nursing, University of South China, Hengyang, Hunan

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022-USC-HL-224

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南华大学医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee University of south china

伦理委员会批准日期:

Date of approved by ethic committee:

2022-12-13 00:00:00

伦理委员会联系人:

刘良专

Contact Name of the ethic committee:

Liangzhuan Liu

伦理委员会联系地址:

湖南省衡阳市蒸湘区常胜西路28号

Contact Address of the ethic committee:

28 West Changsheng Road, Hengyang, Hunan

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 734 8282726

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南华大学护理学院

Primary sponsor:

School of nursing University of South China

研究实施负责(组长)单位地址:

湖南省衡阳市蒸湘区常胜西路28号

Primary sponsor's address:

28 West Changsheng Road, Hengyang, Hunan

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖南省

市(区县):

衡阳市

Country:

China

Province:

Hu'nan

City:

Hengyang

单位(医院):

南华大学护理学院

具体地址:

湖南省衡阳市蒸湘区常胜西路28号

Institution
hospital:

School of nursing University of South China

Address:

28 West Changsheng Road, Hengyang, Hu'nan

经费或物资来源:

2021年湖南省自然科学基金面上项目(项目编号:2021JJ30586)

Source(s) of funding:

General Program of Hunan Natural Science Foundation(No.2021JJ30586)

Target disease:

nasopharyngeal carcinoma

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

半随机对照 

Study design:

Quasi-randomized controlled 

研究目的:

1.通过规范文献检索,对当前鼻咽癌放疗后张口困难筛查、护理、治疗证据进行总结; 2.通过质性访谈,全面了解衡阳市当前鼻咽癌放疗后张口困难防控现况,分析路径实施存在问题; 3.构建基于三级预防理念的鼻咽癌放疗后张口困难的防控措施与临床防控路径。  

Objectives of Study:

1.To summarize the evidence of screening, nursing and treatment of difficulty in mouth opening of nasopharyngeal carcinoma after radiotherapy by standardizing literature search. 2.To fully understand the current situation of difficult prevention and control of radiation-induced trismus of nasopharyngeal carcinoma in Hengyang City and analyze the problems in the implementation of the path. 3.To construct the prevention and control measures and clinical prevention and control pathway of difficulty in radiation-induced trismus of nasopharyngeal carcinoma based on the concept of tertiary prevention.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

质性访谈
(1)肿瘤放疗科临床专家纳入标准:①具有肿瘤科10年以上临床工作或管理经验。②本科及以上学历。③具有中级以上职称。④熟悉鼻咽癌放疗治疗及护理相关领域。⑤具有严谨科学求实的态度,自愿参与本研究。
(2)护士纳入标准:①取得护士执业资格证书;②年龄18~60周岁;③在肿瘤科工作时间≥5年;④自愿参与调查。
(3)放疗患者纳入标准:①依据中华医学会放射肿瘤学分会鼻咽癌临床诊断分期标准,病理学检查确诊为鼻咽癌;②肿瘤淋巴结转移(TNM)系统分期为Ⅰ期至ⅣB期;③正在接受放射治疗或者准备接受放射治疗;④年龄≥18岁;⑤意识清楚,能够进行正常交流;
预实验
(1)接受首程根治性放射治疗。(2)鼻咽肿瘤未侵及颞下窝和颞颌关节区。(3)经组织学或细胞学确诊。(4)颌面部无手术外伤史,无颞颌关节病史。(5)患者上、下门齿尚存,能够准确测量门齿间距。

Inclusion criteria

Qualitative interview
1.the inclusion criteria of clinical experts in oncology radiotherapy department: (1) have more than 10 years clinical work or management experience in oncology department. (2) Bachelor's degree or above. (3) have intermediate or above professional title. (4) familiars with radiotherapy and nursing related fields of nasopharyngeal carcinoma. (5) have a rigorous, scientific and realistic attitude and volunteer to participate in this study.
Pilot study
(1) First course radical radiotherapy. (2) Nasopharyngeal tumors did not invade the infratemporal fossa and temporomandibular joint. (3) The diagnosis was confirmed by histology or cytology. (4) There is no history of surgical trauma and temporomandibular joint disease in maxillofacial region. (5) The patient's upper and lower incisors still exist, which can accurately measure the distance between incisors.
2.the inclusion criteria of nurses were as follows: (1) obtaining nurse practice qualification certificate; (2) 18-60 years old; (3) working in oncology department for more than 5 years; and (4) voluntarily participating in the survey. Exclusion criteria: (1) leaving the post for more than 6 months due to sick leave, maternity leave, breastfeeding, going out to study and other reasons; (2) nurses for further study and internship.
3.inclusion criteria of radiotherapy patients: (1) according to the clinical diagnostic staging criteria of nasopharyngeal carcinoma of radiation Oncology Branch of Chinese Medical Association, nasopharyngeal carcinoma was diagnosed by pathological examination; (2) systematic staging of tumor lymph node metastasis (TNM) was stage Ⅰ to Ⅳ B; (3) patients were receiving or preparing to receive radiotherapy; (4) age ≥ 18 years old; and (5) conscious and able to communicate normally. Exclusion criteria: (1) complicated with other types of malignant tumors, (2) received open surgery or nasal endoscopic surgery.

排除标准:

质性访谈
1.护士排除标准:①因病假、产假、哺乳、外出学习等原因离开岗位≥6个月;②进修和实习的护理人员。
2.患者排除标准:①合并有其他类型恶性肿瘤;②接受开放性手术或鼻内镜手术。
预实验
(1)不能参与康复锻炼的患者,如带喉气管套管、急性肌肉关节扭伤、急性颈脊椎病变、颈脊神经炎、局部皮肤病变影响锻炼者。(2)放疗中断者。(3)患有精神疾患无法收集结局指标者。

Exclusion criteria:

Qualitative interview
1. Exclusion criteria for nurses: ① Leave the post for sick leave, maternity leave, breastfeeding, going out to study and other reasons ≥ 6 months; ② Nursing staff for further study and practice.
2. Exclusion criteria for patients: ① combined with other types of malignant tumors; ② Open surgery or endoscopic surgery.
Pilot study
(1) Patients who can not participate in rehabilitation exercise, such as those with laryngotracheal cannula, acute muscle joint sprain, acute cervical spinal disease, cervical spinal neuritis, and local skin diseases that affect exercise. (2) Interruption of radiotherapy. (3) People with mental disorders who cannot collect outcome indicators.

研究实施时间:

Study execute time:

From 2023-02-01 00:00:00 To 2024-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-04-01 00:00:00 To 2023-10-31 00:00:00  

干预措施:

Interventions:

组别:

干预组

样本量:

36

Group:

intervention group

Sample size:

干预措施:

基于三级预防的临床防控路径

干预措施代码:

Intervention:

Clinical prevention and control path based on three-level prevention

Intervention code:

组别:

对照组

样本量:

36

Group:

control group

Sample size:

干预措施:

常规防控措施

干预措施代码:

Intervention:

Conventional prevention and control measures

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖南 

市(区县):

衡阳 

Country:

China 

Province:

Hu'nan 

City:

Hengyang 

单位(医院):

南华大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of University of South China

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖南 

市(区县):

衡阳 

Country:

China 

Province:

Hu'nan 

City:

Hengyang 

单位(医院):

南华大学附属第二医院 

单位级别:

三级甲等 

Institution
hospital:

The Second Affiliated Hospital of University of South China

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖南 

市(区县):

衡阳 

Country:

China 

Province:

Hu'nan 

City:

Hengyang 

单位(医院):

南华大学附属第三医院 

单位级别:

三级甲等 

Institution
hospital:

The Third Affiliated Hospital of University of South China

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖南 

市(区县):

衡阳 

Country:

China 

Province:

Hu'nan 

City:

Hengyang 

单位(医院):

南华大学附属南华医院 

单位级别:

三级甲等 

Institution
hospital:

The Nanhua Hospital of University of South China

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖南 

市(区县):

衡阳 

Country:

China 

Province:

Hu'nan 

City:

Hengyang 

单位(医院):

衡阳市中心医院 

单位级别:

三级甲等 

Institution
hospital:

Central Hospital of Hengyang

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

门齿距

指标类型:

主要指标

Outcome:

incisor

Type:

Primary indicator

测量时间点:

入院当天、出院前1天、出院后3个月

测量方法:

使用标准卡尺进行测量

Measure time point of outcome:

On the day of admission, 1 day before discharge and 3 months after discharge

Measure method:

standard caliper

指标中文名:

生活质量调查量表

指标类型:

主要指标

Outcome:

EOCRTC QLQ-C30 V3.0

Type:

Primary indicator

测量时间点:

入院当天、出院前1天、出院后3个月

测量方法:

量表

Measure time point of outcome:

On the day of admission, 1 day before discharge and 3 months after discharge

Measure method:

Scale

指标中文名:

一般资料调查表

指标类型:

主要指标

Outcome:

General information questionnaire

Type:

Primary indicator

测量时间点:

入院当天、出院前1天、出院后3个月

测量方法:

问卷

Measure time point of outcome:

On the day of admission, 1 day before discharge and 3 months after discharge

Measure method:

questionnaire

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

选取衡阳市某三甲医院放疗科鼻咽癌放疗患者72例为研究对象。根据随机数字表法分为对照组和干预组。具体随机方案:①编号:将研究对象按入院先后顺序进行编号(01-72号);②产生随机数:从随机数字表的第2行第1列开始依次取72个随机数(重复数字跳过)赋予患者编号,再将随机数由小到大依次编号;③随机分组:规定随机数字秩次1-36为对照组,37-72为干预组。

Randomization Procedure (please state who generates the random number sequence and by what method):

The researcher used random number table to generate random numbers: ① Number: Number the subjects according to the order of admission (No. 01-72); ② Generate random number: from the second row and the first column of the random number table, take 72 random numbers (skip repeated numbers) and assign them

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

未说明

Blinding:

Not stated

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2024年6月1日,临床试验公共管理平台,http://www.medresman.org

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

June 1, 2024, ResMan, a public management platform for clinical trials, http://www.medresman.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表和电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form and Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2023-03-08 02:50:03